Literature DB >> 10766744

Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.

Y Imai1, A Moralez, U Andag, J B Clarke, W H Busby, D R Clemmons.   

Abstract

Insulin-like growth factor-binding protein-3 and -5 (IGFBP-3 and -5) have been shown to bind insulin-like growth factor-I and -II (IGF-I and -II) with high affinity. Previous studies have proposed that the N-terminal region of IGFBP-5 contains a hydrophobic patch between residues 49 and 74 that is required for high affinity binding. These studies were undertaken to determine if mutagenesis of several of these residues resulted in a reduction of the affinity of IGFBP-3 and -5 for IGF-I. Substitutions for residues 68, 69, 70, 73, and 74 in IGFBP-5 (changing one charged residue, Lys(68), to a neutral one and the four hydrophobic residues to nonhydrophobic residues) resulted in an approximately 1000-fold reduction in the affinity of IGFBP-5 for IGF-I. Substitutions for homologous residues in IGFBP-3 also resulted in a >1000-fold reduction in affinity. The physiologic consequence of this reduction was that IGFBP-3 and -5 became very weak inhibitors of IGF-I-stimulated cell migration and DNA synthesis. Likewise, the ability of IGFBP-5 to inhibit IGF-I-stimulated receptor phosphorylation was attenuated. These changes did not appear to be because of alterations in protein folding induced by mutagenesis, because the IGFBP-5 mutant was fully susceptible to proteolytic cleavage by a specific IGFBP-5 protease. In summary, residues 68, 69, 70, 73, and 74 in IGFBP-5 appear to be critical for high affinity binding to IGF-I. Homologous residues in IGFBP-3 are also required, suggesting that they form a similar binding pocket and that for both proteins these residues form an important component of the core binding site. The availability of these mutants will make it possible to determine if there are direct, non-IGF-I-dependent effects of IGFBP-3 and -5 on cellular physiologic processes in cell types that secrete IGF-I.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766744     DOI: 10.1074/jbc.M000070200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  What's new in the IGF-binding proteins?

Authors:  Steven A Rosenzweig
Journal:  Growth Horm IGF Res       Date:  2004-10       Impact factor: 2.372

2.  The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5.

Authors:  W Zesławski; H G Beisel; M Kamionka; W Kalus; R A Engh; R Huber; K Lang; T A Holak
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

Review 3.  Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study.

Authors:  James Beattie; Kirsten Phillips; John H Shand; Malgorzata Szymanowska; David J Flint; Gordon J Allan
Journal:  Mol Cell Biochem       Date:  2007-09-25       Impact factor: 3.396

4.  A crayfish insulin-like-binding protein: another piece in the androgenic gland insulin-like hormone puzzle is revealed.

Authors:  Ohad Rosen; Simy Weil; Rivka Manor; Ziv Roth; Isam Khalaila; Amir Sagi
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

Review 5.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

6.  Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Authors:  Iván P Uray; Qiang Shen; Hye-Sook Seo; HeeTae Kim; William W Lamph; Reid P Bissonnette; Powel H Brown
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

7.  Dual roles of CCN proteins in breast cancer progression.

Authors:  Celina G Kleer
Journal:  J Cell Commun Signal       Date:  2016-08-12       Impact factor: 5.782

8.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

9.  Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions.

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2008-02-21

10.  Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha.

Authors:  Giovanna Zappala; Cem Elbi; Joanna Edwards; Julie Gorenstein; Matthew M Rechler; Nisan Bhattacharyya
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.